留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

KRAS基因3′UTR多态性与云南汉族人群宫颈癌及宫颈上皮内瘤变的相关性

郭妮 张承 洪超 刘伟鹏 姚宇峰 严志凌

郭妮, 张承, 洪超, 刘伟鹏, 姚宇峰, 严志凌. KRAS基因3′UTR多态性与云南汉族人群宫颈癌及宫颈上皮内瘤变的相关性[J]. 昆明医科大学学报, 2024, 45(2): 14-22. doi: 10.12259/j.issn.2095-610X.S20240203
引用本文: 郭妮, 张承, 洪超, 刘伟鹏, 姚宇峰, 严志凌. KRAS基因3′UTR多态性与云南汉族人群宫颈癌及宫颈上皮内瘤变的相关性[J]. 昆明医科大学学报, 2024, 45(2): 14-22. doi: 10.12259/j.issn.2095-610X.S20240203
Ni GUO, Cheng ZHANG, Chao HONG, Weipeng LIU, Yufeng YAO, Zhiling YAN. Correlation of KRAS Gene 3′ UTR Polymorphisms with Cervical Cancer and Cervical Intraepithelial Neoplasia in Chinese Han Population in Yunnan Province[J]. Journal of Kunming Medical University, 2024, 45(2): 14-22. doi: 10.12259/j.issn.2095-610X.S20240203
Citation: Ni GUO, Cheng ZHANG, Chao HONG, Weipeng LIU, Yufeng YAO, Zhiling YAN. Correlation of KRAS Gene 3′ UTR Polymorphisms with Cervical Cancer and Cervical Intraepithelial Neoplasia in Chinese Han Population in Yunnan Province[J]. Journal of Kunming Medical University, 2024, 45(2): 14-22. doi: 10.12259/j.issn.2095-610X.S20240203

KRAS基因3′UTR多态性与云南汉族人群宫颈癌及宫颈上皮内瘤变的相关性

doi: 10.12259/j.issn.2095-610X.S20240203
基金项目: 国家自然科学基金资助项目(82103190);云南省基础研究计划项目(202201AY070001-139;202201AU070163)
详细信息
    作者简介:

    郭妮(1996~),女,云南保山人,在读硕士研究生,主要从事感染性疾病及肿瘤的免疫遗传学研究工作

    通讯作者:

    严志凌,E-mail:yanzhiling2021@126.com

  • 中图分类号: R735.7

Correlation of KRAS Gene 3′ UTR Polymorphisms with Cervical Cancer and Cervical Intraepithelial Neoplasia in Chinese Han Population in Yunnan Province

  • 摘要:   目的  探究KRAS基因中3′ UTR区域的rs712和rs7973450位点与云南汉族人群宫颈癌(cervical cancer,CC)和宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)的相关性。  方法  共纳入CIN患者461例、CC患者961例及其健康对照983例,采用TaqMan探针法进行基因分型检测,并分析2个SNP位点与CIN及CC的相关性。  结果  rs7973450位点的A等位基因可能是CIN(P = 0.004,OR = 0.651,95%CI 0.487 ~ 0.871)与CC(P = 7.00 × 10-4OR = 0.667,95%CI 0.529 ~ 0.844)发生的保护性因素。rs712位点在CIN组、CC组和对照组间等位基因和基因型分布频率的差异无统计学意义(P > 0.017);单倍型分析的结果显示,单倍型rs712A-rs7973450G与更高的CIN(P = 4.00 × 10-4OR = 1.714,95%CI 1.269 ~ 2.314)和CC(P = 3.84 × 10-5OR = 1.667,95%CI 1.305 ~ 2.131)发生风险相关;单倍型rs712A-rs7973450A则与更低的CC发生风险相关(P = 0.012,OR = 0.790,95%CI 0.658 ~ 0.950)。  结论  位于KRAS基因3′ UTR区域的SNP位点rs7973450的A等位基因可能是云南汉族人群CIN和CC发生的保护性因素。
  • 表  1  研究对象分组及均衡性检验[($\bar x \pm s $)/n(%)]

    Table  1.   Grouping of study subjects [($\bar x \pm s $)/n(%)]

    资料特征CIN组CC组对照组FP
    人数(n 416 961 983
    年龄分布(岁) 45.00 ± 9.55 46.25 ± 9.81 45.77 ± 8.87 2.605 0.074
    临床分期
     CIN2 51(12.3)
     CIN3 365(87.7)
     Ⅰ 624(64.9)
     Ⅱ 270(29.1)
     Ⅲ ~ Ⅳ 67(7.0)
    病理类型
     SCC 799(83.1)
     AC 162(16.9)
    下载: 导出CSV

    表  2  KRAS基因2个SNP位点在CIN组、CC组和对照组间等位基因和基因型频率分布[n(%)]

    Table  2.   The allelic and genotypic frequency distribution of the SNPs in KRAS gene among the CIN,CC and control groups [n(%)]

    SNPs等位基因/基因型对照组CIN组CC组χ²PHWEaP
    rs712 A 405(20.6) 181(21.8) 412(21.4) 0.633 0.729 0.469
    C 1561(79.4) 651(78.2) 1510(78.6)
    A/A 38(3.9) 24(5.8) 46(4.8) 2.726 0.605
    A/C 329(33.4) 133(32.0) 320(33.3)
    C/C 616(62.7) 259(62.3) 595(61.9)
    rs7973450 A 1837(93.4) 751(90.3) 1739(90.5) 13.782 0.001* 0.093
    G 129(6.6) 81(9.7) 183(9.5)
    A/A 855(87.0) 337(81.0) 783(81.4) 14.89 0.005*
    A/G 127(12.9) 77(18.5) 173(18.0)
    G/G 1(0.1) 2(0.5) 5(0.6)
      *P < 0.017(Bonferroni校正,n = 3)。
    下载: 导出CSV

    表  3  rs7973450在CIN组、CC组和对照组间等位基因和基因型频率的两两比较[n(%)]

    Table  3.   Pairwise comparison of allele and genotype frequencies of rs7973450 among CIN group,CC group,and control group [n(%)]

    等位基因/基因型AGA/AA/GG/G
    对照组 1837(93.4) 129(6.6) 855(87.0) 127(12.9) 1(0.1)
    CIN组 751(90.3) 81(9.7) 337(81.0) 77(18.5) 2(0.5)
    CC组 1739(90.5) 183(9.5) 783(81.4) 173(18.0) 5(0.6)
    CIN vs 对照组 χ2 8.484 9.444
    P 0.004* 0.009*
    OR(95%CI 0.651(0.487 ~ 0.871)
    CC vs 对照组 χ2 11.535 12.637
    P 7.00 × 10-4* 0.002*
    OR(95%CI 0.667(0.529 ~ 0.844)
    CC vs CIN χ2 0.031 0.058
    P 0.861 0.971
    OR(95%CI 1.024(0.778 ~ 1.350)
    下载: 导出CSV

    表  4  KRAS基因中2个SNP在不同病理类型CC病例组和对照组间等位基因和基因型分布情况[n(%)]

    Table  4.   The allelic and genotypic distribution of two SNPs inKRASgene among different pathological types of CC case and control groups [n(%)]

    SNPs等位基因/基因型对照组SCC组AC组χ²P
    rs712 A 405(20.6) 342(21.4) 70(21.6) 0.416 0.812
    C 1561(79.4) 1256(78.6) 254(78.4)
    A/A 38(3.9) 35(4.4) 11(6.8) 3.684 0.450
    A/C 329(33.4) 272(34.0) 48(29.6)
    C/C 616(62.7) 492(61.6) 103(63.6)
    rs7973450 A 1837(93.4) 1452(90.9) 287(88.6) 13.438 0.001*
    G 129(6.6) 146(9.1) 37(11.4)
    A/A 855(87.0) 655(82.0) 128(79.0) 24.134 7.51×10−5*
    A/G 127(12.9) 142(17.8) 31(19.1)
    G/G 1(0.1) 2(0.2) 3(1.9)
      *P < 0.017(Bonferroni校正,n = 3)。
    下载: 导出CSV

    表  5  rs7973450在SCC组、AC组和对照组间等位基因和基因型频率的两两比较[n(%)]

    Table  5.   Pairwise comparison of allele and genotype frequencies of rs7973450 among SCC group,AC group,and control group [n(%)]

    等位基因/基因型AGA/AA/GG/G
    对照组 1837(93.4) 129(6.6) 855(87.0) 127(12.9) 1(0.1)
    SCC 1452(90.9) 146(9.1) 655(82.0) 142(17.8) 2(0.2)
    AC 287(88.6) 37(11.4) 128(79.0) 31(19.1) 3(1.9)
    SCC vs 对照组 χ2 8.207 8.754
    P 0.004* 0.013*
    OR(95%CI 0.698(0.546 ~ 0.894)
    AC vs 对照组 χ2 9.764 17.117
    P 0.002* 2.00×10−4*
    OR(95%CI 0.545(0.370 ~ 0.801)
    SCC vs AC χ2 1.630 6.924
    P 0.202 0.031
    OR(95%CI 1.282(0.875 ~ 1.879)
    下载: 导出CSV

    表  6  KRAS基因中2个SNP在不同临床分期CC病例组和对照组间等位基因和基因型分布情况[n(%)]

    Table  6.   The allelic and genotypic distribution of two SNPs in KRAS gene among different clinical stages of CC case and control groups [n(%)]

    SNPs等位基因/基因型对照组Ⅰ期Ⅱ期Ⅲ~Ⅳ期χ2P
    rs712 A 405(20.6) 276(22.1) 105(19.4) 31(23.1) 2.279 0.517
    C 1561(79.4) 972(77.9) 435(80.6) 103(76.9)
    A/A 38(3.9) 33(5.3) 9(3.3) 4(6.0) 3.445 0.751
    A/C 329(33.4) 210(33.6) 87(32.2) 23(34.3)
    C/C 616(62.7) 381(61.1) 174(64.5) 40(59.7)
    rs7973450 A 1837(93.4) 1132(90.7) 488(90.4) 119(88.8) 12.140 0.007*
    G 129(6.6) 116(9.3) 52(9.6) 15(11.2)
    A/A 855(87.0) 510(81.7) 220(81.5) 53(79.1) 16.066 0.013
    A/G 127(12.9) 112(18.0) 48(17.8) 13(19.4)
    G/G 1(0.1) 2(0.3) 2(0.7) 1(1.5)
      *P < 0.008(Bonferroni校正,n = 6)。
    下载: 导出CSV

    表  7  rs7973450在不同临床分期CC病例组和对照组间等位基因分布频率的两两比较[n(%)]

    Table  7.   Pairwise comparison of allele distribution frequencies of rs7973450 among different clinical stages of CC case groups and control group [n(%)]

    等位基因/基因型AG
    对照组 1837(93.4) 129(6.6)
    Ⅰ期 1132(90.7) 116(9.3)
    Ⅱ期 488(90.4) 52(9.6)
    Ⅲ~Ⅳ期 119(88.8) 15(11.2)
    Ⅰ期 vs 对照组 χ2 8.099
    P 0.004*
    OR(95%CI 0.685(0.528 ~ 0.890)
    Ⅱ期 vs 对照组 χ2 5.951
    P 0.015
    OR(95%CI 0.659(0.470 ~ 0.923)
    Ⅲ~Ⅳ期 vs 对照组 χ2 4.215
    P 0.040
    OR(95%CI 0.557(0.316 ~ 0.981)
    下载: 导出CSV

    表  8  KRAS基因2个SNP位点在CIN组、CC组和对照组间的单倍型分析[n(%)]

    Table  8.   Haplotype analysis of two SNP in KRAS gene among CIN,CC and control groups [n(%)]

    位点 rs712- rs7973450
    基因型 A/A A/G C/A
    对照组 292.67(14.9) 112.33(5.7) 1544.3(78.6)
    CIN组 102.31(12.3) 78.69(9.5) 648.7(78.0)
    CC组 234.71(12.2) 177.29(9.2) 1504.30(78.3)
    CIN vs 对照组 D' 0.886
    r2 0.241
    OR(95%CI 0.796(0.625 ~ 1.014) 1.714(1.269 ~ 2.314) 0.940(0.771 ~ 1.145)
    P 0.064 4×10−4* 0.539
    CC vs 对照组 D' 0.910
    r2 0.272
    OR(95%CI 0.790(0.658 ~ 0.950) 1.667(1.305 ~ 2.131) 0.958(0.821 ~ 1.117)
    P 0.012* 3.84×10−5* 0.582
    下载: 导出CSV
  • [1] Sung H,Ferlay J,Siegel R L,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249. doi: 10.3322/caac.21660
    [2] Zheng R,Zhang S,Zeng H,et al. Cancer incidence and mortality in China,2016[J]. Journal of the National Cancer Center,2022,2(1):1-9. doi: 10.1016/j.jncc.2022.02.002
    [3] Crosbie E J,Einstein M H,Franceschi S,et al. Human papillomavirus and cervical cancer[J]. Lancet,2013,382(9895):889-899. doi: 10.1016/S0140-6736(13)60022-7
    [4] Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application[J]. Nature reviews Cancer,2002,2(5):342-350. doi: 10.1038/nrc798
    [5] Bowden S J,Bodinier B,Kalliala I,et al. Genetic variation in cervical preinvasive and invasive disease: A genome-wide association study[J]. Lancet Oncol,2021,22(4):548-557. doi: 10.1016/S1470-2045(21)00028-0
    [6] Chen B,Yi C,Wang J,et al. A comprehensive study of CD44 rs 187115 variant and cancer risk in a central Chinese population[J]. J Cell Biochem,2019,120(8):12949-12957. doi: 10.1002/jcb.28566
    [7] Wang F,Shan S,Huo Y,et al. MiR-155-5p inhibits PDK1 and promotes autophagy via the mTOR pathway in cervical cancer[J]. Int J Biochem Cell Biol,2018,99:91-99. doi: 10.1016/j.biocel.2018.04.005
    [8] Huang L,Guo Z,Wang F,et al. KRAS mutation: from undruggable to druggable in cancer[J]. Signal Transduct Target Ther,2021,6(1):386. doi: 10.1038/s41392-021-00780-4
    [9] Wang D, Liu Q, Ren Y, et al. Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival [J]. Biosci Rep, 2021, 41(4): BSR20204136.
    [10] Paranjape T,Heneghan H,Lindner R,et al. A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis[J]. Lancet Oncol,2011,12(4):377-386. doi: 10.1016/S1470-2045(11)70044-4
    [11] Li Z H,Pan X M,Han B W,et al. A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer[J]. Tumour Biol,2013,34(5):3159-3163. doi: 10.1007/s13277-013-0885-x
    [12] Hussen B M,Hidayat H J,Salihi A,et al. MicroRNA: A signature for cancer progression[J]. Biomed Pharmacother,2021,138:111528. doi: 10.1016/j.biopha.2021.111528
    [13] Kim M,Slack F J. MicroRNA-mediated regulation of KRAS in cancer[J]. J Hematol Oncol,2014,7:84. doi: 10.1186/s13045-014-0084-2
    [14] 国家癌症中心,国家肿瘤质控中心宫颈癌质控专家委员会. 中国宫颈癌规范诊疗质量控制指标(2022版)[J]. 中华肿瘤杂志,2022,44(7):615-22.
    [15] Bhatla N,Aoki D,Sharma D N,et al. Cancer of the cervix uteri[J]. Int J Gynaecol Obstet,2018,143(S2):22-36.
    [16] WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention [M]. 2nd ed. Geneva: World Health Organization, 2021.
    [17] Simanshu D K,Nissley D V,Mccormick F. RAS Proteins and Their Regulators in Human Disease[J]. Cell,2017,170(1):17-33. doi: 10.1016/j.cell.2017.06.009
    [18] Zhu G,Pei L,Xia H,et al. Role of oncogenic KRAS in the prognosis,diagnosis and treatment of colorectal cancer[J]. Molecular Cancer,2021,20(1):143. doi: 10.1186/s12943-021-01441-4
    [19] Li Z,Chen Y,Wang D,et al. Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients[J]. J Int Med Res,2012,40(4):1589-1598. doi: 10.1177/147323001204000439
    [20] Fernández-Medarde A,Santos E. Ras in cancer and developmental diseases[J]. Genes Cancer,2011,2(3):344-358. doi: 10.1177/1947601911411084
    [21] Hu H, Cheng R, Wang Y, et al. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47 [J]. J Clin Invest, 2023, 133(2): e153470.
    [22] Kumar M S,Swanton C. KRAS 3′-UTR variants and stratification of breast-cancer risk[J]. Lancet Oncol,2011,12(4):318-319. doi: 10.1016/S1470-2045(11)70065-1
    [23] Nelson H H,Christensen B C,Plaza S L,et al. KRAS mutation,KRAS-LCS6 polymorphism,and non-small cell lung cancer[J]. Lung Cancer,2010,69(1):51-3. doi: 10.1016/j.lungcan.2009.09.008
    [24] Ibrahim H, Lim Y C. KRAS -associated microRNAs in colorectal cancer[J] 2020, 14(2): 454.
    [25] Liu H,Huang J,Peng J,et al. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway[J]. Mol Cancer,2015,14:59.
    [26] Johnson S M,Grosshans H,Shingara J,et al. RAS is regulated by the let-7 microRNA family[J]. Cell,2005,120(5):635-647. doi: 10.1016/j.cell.2005.01.014
    [27] Ahmed E A, Rajendran P, Scherthan H. The microRNA-202 as a Diagnostic Biomarker and a Potential Tumor Suppressor [J]. Int J Mol Sci, 2022, 23(11): 5870.
    [28] Gallegos-Arreola M P,Z ú ñiga-Gonz á lez G M,Gómez-Mariscal K,et al. Association of rs712 polymorphism in a let-7 microRNA-binding site of KRAS gene with colorectal cancer in a Mexican population[J]. Iran J Basic Med Sci,2019,22(3):324-327.
    [29] Jiang Q H,Peng H X,Zhang Y,et al. rs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in Chinese population[J]. OncoTargets and Therapy,2015,8:3041-3045.
    [30] Huang X,Yang Y,Guo Y,et al. Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer[J]. Genet Mol Res,2015,14(4):16913-16920. doi: 10.4238/2015.December.14.19
    [31] Chin L J,Ratner E,Leng S,et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non–small cell lung cancer risk[J]. Cancer Research,2008,68(20):8535-8540. doi: 10.1158/0008-5472.CAN-08-2129
    [32] Fu W,Zhuo Z,Hua R X,et al. Association of KRAS and NRAS gene polymorphisms with Wilms tumor risk: A four-center case-control study[J]. Aging (Albany NY),2019,11(5):1551-1563. doi: 10.18632/aging.101855
    [33] Guan Q,Yuan L,Lin A,et al. KRAS gene polymorphisms are associated with the risk of glioma: A two-center case-control study[J]. Transl Pediatr,2021,10(3):579-586. doi: 10.21037/tp-20-359
    [34] Lin A,Hua R X,Tang J,et al. KRAS rs7973450 A>G increases neuroblastoma risk in Chinese children: A four-center case-control study[J]. Onco Targets Ther,2019,12:7289-7295. doi: 10.2147/OTT.S223220
    [35] Insodaite R,Smalinskiene A,Liutkevicius V,et al. Associations of Polymorphisms Localized in the 3′ UTR Regions of the KRAS,NRAS,MAPK1 genes with laryngeal squamous cell carcinoma[J]. Genes,2021,12(11):1679. doi: 10.3390/genes12111679
  • [1] 潘虹, 邓都尉, 刘石林.  彩超Adler分级对宫颈癌的诊断分析及与病理指标的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240517
    [2] 牛志鑫, 汤丽华, 史磊, 洪超, 姚宇峰, 严志凌.  MAPK1NRAS基因多态性与云南汉族人群宫颈上皮内瘤变的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240502
    [3] 程甜甜, 尹文卅, 王佳, 卢玉梅, 陈炫羽, 聂胜洁, 刘林林.  TMTC1基因多态性与精神分裂症的关联性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231014
    [4] 师雨晗, 李菁, 刘舒媛, 赵婷, 杨净思, 史荔, 梁疆莉.  壮族人群ERAP基因多态性与脊灰疫苗序贯免疫诱导的抗体应答的相关性分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230711
    [5] 李抒瑾, 杨艳飞, 苏敏, 凌昱, 饶艳琼, 崔继华.  儿童注意缺陷多动障碍共病情绪问题的单核苷酸多态性研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230420
    [6] 伍蓉霜, 彭江丽, 陈永刚, 陈洁, 马国伟, 李先蕊, 李谢, 余春红.  SLC2A9基因单核苷酸多态性与吡嗪酰胺致高尿酸血症易感性关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230409
    [7] 李东云, 冮顺奎, 李捷, 张明星, 李雷.  ABCG2、SLC2A9、SLC17A3和 PRKG2基因单核苷酸位点多态性与哈尼族人群痛风的关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210320
    [8] 谭丁及, 尹洪莉, 朱锐, 张曦, 余鑫, 飞勇, 李昕, 段铭, 何亮, 杨宏英.  宫颈上皮内瘤变和宫颈癌患者的阴道微生态特点, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210821
    [9] 刘洋, 黄娅娟, 廖婧, 孙春意, 翟淑娟, 周红林.  宫颈病变中应用FISH技术检测C-MYC基因及HC2技术、SPR技术检测HPV结果的相关性, 昆明医科大学学报.
    [10] 翟淑娟, 潘景, 孙春意, 刘洋, 杨莹莹, 周红林.  p62、OPTN在宫颈癌中的表达及其与HPV的相关性, 昆明医科大学学报.
    [11] 李轶梅.  宫颈环行电刀切除术治疗宫颈上皮内瘤变的临床价值, 昆明医科大学学报.
    [12] 刘城秀.  云南汉族人群TNF-α基因和ALCAM基因多态性与HCV慢性感染的相关性, 昆明医科大学学报.
    [13] 朱胜章.  宫颈液基细胞学检查在贵州黔南地区宫颈癌筛查中的临床运用, 昆明医科大学学报.
    [14] 向茜.  维生素D受体基因FokI位点单核苷酸多态性与糖尿病肾病的相关性, 昆明医科大学学报.
    [15] 刘丽丽.  染色体9p21单核苷酸多态性与冠心病/心肌梗死相关性的研究进展, 昆明医科大学学报.
    [16] 戴书颖.  IL-4基因启动子SNP-1098T>G和-590C>T多态性与云南汉族人群HCV慢性感染的相关性研究, 昆明医科大学学报.
    [17] 李莹.  云南汉族人群IL-10基因启动子多态性与HCV慢性感染的相关性研究, 昆明医科大学学报.
    [18] 严志凌.  宿主p53基因多态性与HPV16 感染、宫颈癌发生发展的相关性, 昆明医科大学学报.
    [19] 杨小蕾.  STAT4基因单核苷酸多态性与云南汉族人群SLE发病的相关性研究, 昆明医科大学学报.
    [20] 黄雅.  Brn-3a、PPAR-γ在宫颈癌及癌前病变中的表达, 昆明医科大学学报.
  • 加载中
计量
  • 文章访问数:  741
  • HTML全文浏览量:  463
  • PDF下载量:  19
  • 被引次数: 0
出版历程
  • 收稿日期:  2024-01-16
  • 网络出版日期:  2024-02-27
  • 刊出日期:  2024-02-25

目录

    /

    返回文章
    返回